Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma - Poll - MDSpire

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients

  • By

  • February 9, 2026

  • 3 min

Share

Original Source(s)

Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma

  • by

  • February 9, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Bilateral renal metastasis following radical prostatectomy for prostate cancer: a case report

Novel approaches for separating graft-versus-leukemia effects from graft-versus-host disease